Effects Of Polyethylene Glycol Loxenatide Combined With Dapagliflozin On Obesity And Metabolic Related Indexes In Overweight Or Obese T2DM Patients

Objective: To observe and analyze the effect of polyethylene glycol loxenatide(PEX168)combined with Dapagliflozin(DAPA)on obesity and metabolic related clinical indicators in newly treated overweight or obese type 2 diabetes patients,and provide evidence-based medicine basis for clinical treatment of overweight or obese T2 DM patients.Methods: 102 overweight or obese T2 DM patients who were treated in the endocrine department or inpatient department of The First Affiliated Hospital of Wannan Medical College from June 2021 to June 2022 were retrospectively collected as observation objects.They were divided into two groups according to the drug use,51 in the PEX168+DAPA group and 51 in the DAPA group.The PEX168+DAPA group was given PEX168 0.2 mg subcutaneous injection once a week at a fixed time,and the DAPA group was given 10 mg DAPA once a day before breakfast.The DAPA group was given DAPA 10 mg DAPA once a day before breakfast for 6 months.The general data and laboratory indicators of the two groups before and after treatment were collected,including body weight,Waist hip ratio(WHR),body mass index(BMI)Fasting plasma glucose(FPG),2h postprandial blood glucose(2h PG),glycated hemoglobin(Hb A1c),total cholesterol(TG),triglyceride(TC),low density lipoprotein(LDL-C),high density lipoprotein(HDL-C),incidence of hypoglycemia,the incidence of adverse reactions were analyzed statistically.Results:(1)According to the inclusion criteria,102 patients were finally included in the study.Among them,2 patients in the PEX168+DAPA group had severe gastrointestinal reactions and withdrew from the group.2 patients in the DAPA group lost their follow-up.Finally,98 patients completed the study.Among them,there were 49 cases in the PEX168+DAPA group and 49 cases in the DAPA group.There was no significant difference in the general data and laboratory indicators of the two groups before treatment(P>0.05).(2)After half a year of treatment,the blood glucose related indexes FBG,2h PG and Hb A1 c in the two groups decreased compared with those before treatment(P<0.05),and the blood glucose indexes in the PEX168+DAPA group were significantly lower than those in the DAPA group(P<0.05).(3)After half a year of treatment,the obesity related indexes of weight,BMI and WHR in the two groups were significantly lower than those before treatment(P<0.05),and the obesity related indexes in the PEX168+DAPA group were significantly lower than those in the DAPA group(P<0.05).(4)After half a year of treatment,TG,TC and LDL-C of patients in both groups decreased compared with those before treatment(P<0.05),and TG,TC and LDL-C in PEX168+DAPA group were significantly lower than those in DAPA group(P<0.05);HDL-C of patients in both groups increased compared with that before treatment(P<0.05),and HDL-C in PEX168+DAPA group was significantly higher than that in DAPA group(P<0.05).(5)During the follow-up period,there was no significant difference in the incidence of hypoglycemia between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:(1)For overweight or obese T2 DM patients,DAPA showed good weight loss and hypoglycemic effect,and improved blood lipid distribution to some extent;(2)For overweight or obese T2 DM patients,PEX168 combined with DAPA has a synergistic effect in reducing weight,reducing blood sugar,and improving blood lipid distribution,and has a more significant effect than DAPA alone,which is a safe and effective choice for such patients.